What is William Blair’s Estimate for Medtronic Q3 Earnings?

Medtronic plc (NYSE:MDT) – Investment analysts at William Blair decreased their Q3 2025 EPS estimates for Medtronic in a research note issued to investors on Tuesday, November 19th. William Blair analyst M. Andrew now forecasts that the medical technology company will earn $1.36 per share for the quarter, down from their prior estimate of $1.37. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic’s Q4 2025 earnings at $1.62 EPS, FY2025 earnings at $5.46 EPS and Q2 2026 earnings at $1.43 EPS.

A number of other research firms have also weighed in on MDT. Truist Financial boosted their target price on shares of Medtronic from $90.00 to $93.00 and gave the stock a “hold” rating in a research report on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research report on Monday. Evercore ISI boosted their target price on shares of Medtronic from $100.00 to $104.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. UBS Group raised shares of Medtronic from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $76.00 to $90.00 in a research report on Thursday, August 15th. Finally, Oppenheimer boosted their target price on shares of Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a research report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $95.19.

Medtronic Trading Up 0.7 %

Shares of NYSE:MDT opened at $84.71 on Thursday. The stock has a market capitalization of $108.63 billion, a PE ratio of 25.90, a P/E/G ratio of 2.42 and a beta of 0.84. The company has a current ratio of 1.84, a quick ratio of 1.61 and a debt-to-equity ratio of 0.51. Medtronic has a 1 year low of $75.96 and a 1 year high of $92.68. The firm has a fifty day moving average price of $89.07 and a 200 day moving average price of $84.84.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.01. The firm had revenue of $8.40 billion during the quarter, compared to analysts’ expectations of $8.27 billion. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. Medtronic’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.25 earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Anchor Investment Management LLC raised its position in Medtronic by 1.2% in the third quarter. Anchor Investment Management LLC now owns 107,518 shares of the medical technology company’s stock worth $9,680,000 after purchasing an additional 1,271 shares in the last quarter. Tudor Financial Inc. bought a new stake in Medtronic during the third quarter worth about $586,000. Chelsea Counsel Co. bought a new stake in Medtronic during the third quarter worth about $45,000. Te Ahumairangi Investment Management Ltd grew its stake in Medtronic by 4.1% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 52,321 shares of the medical technology company’s stock worth $4,684,000 after buying an additional 2,050 shares during the last quarter. Finally, TCW Group Inc. grew its stake in Medtronic by 31.5% during the third quarter. TCW Group Inc. now owns 99,673 shares of the medical technology company’s stock worth $8,974,000 after buying an additional 23,900 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.